Core Insights - Integra LifeSciences Holdings Corporation commends the Centers for Medicare & Medicaid Services (CMS) for its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules, which include all of Integra's dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes classified as skin substitutes [1][2] Group 1: Company Overview - Integra LifeSciences is a global medical technology leader focused on restoring lives through innovation in neurosurgery and tissue reconstruction, with a portfolio of differentiated technologies trusted by healthcare professionals [3] - The company offers a diverse range of products, including Integra matrices, PriMatrix, Cytal, and AmnioExcel, utilizing four unique technology platforms for complex wound reconstruction cases [1][3] Group 2: Industry Impact - The new CMS ruling is seen as a pivotal advancement for the industry, allowing for uniform reimbursement rates across care settings, which will expand access to Integra's product portfolio [2] - The company believes that the new policy will reward innovation, quality, and patient outcomes, areas where it has consistently led [2]